| Lippincott’s illustrated reviews: biochemistry RA Harvey, DR Ferrier Lippincott Williams & Wilkins, 2017 | 357 | 2017 |
| Lippincott's illustrated reviews: Pharmacology MJ Mycek, SB Gertner, MM Perper Wolters Kluwer Health/Lippincott Williams & Wilkins 526, 530-541, 2012 | 215 | 2012 |
| Sibutramine: a serotonin–norepinephrine reuptake-inhibitor for the treatment of obesity CA Luque, JA Rey Annals of Pharmacotherapy 33 (9), 968-978, 1999 | 215 | 1999 |
| The discovery and status of sibutramine as an anti-obesity drug CA Luque, JA Rey European journal of pharmacology 440 (2-3), 119-128, 2002 | 188 | 2002 |
| Vortioxetine (brintellix): a new serotonergic antidepressant A D’Agostino, CD English, JA Rey Pharmacy and Therapeutics 40 (1), 36, 2015 | 142 | 2015 |
| Intranasal esketamine (SpravatoTM) for use in treatment-resistant depression in conjunction with an oral antidepressant R Bahr, A Lopez, JA Rey Pharmacy and Therapeutics 44 (6), 340, 2019 | 107 | 2019 |
| Tetrabenazine (Xenazine), an FDA-approved treatment option for Huntington’s disease–related chorea T Yero, JA Rey Pharmacy and Therapeutics 33 (12), 690, 2008 | 97 | 2008 |
| Naltrexone/bupropion ER (Contrave): newly approved treatment option for chronic weight management in obese adults MM Sherman, S Ungureanu, JA Rey Pharmacy and Therapeutics 41 (3), 164, 2016 | 89 | 2016 |
| Lorcaserin (Belviq): a selective serotonin 5-HT2C agonist in the treatment of obesity A Gustafson, C King, JA Rey Pharmacy and Therapeutics 38 (9), 525, 2013 | 70 | 2013 |
| Psychiatry: Role of Risperidone in Children with Autism Spectrum Disorder B Chavez, M Chavez-Brown, JA Rey Annals of Pharmacotherapy 40 (5), 909-916, 2006 | 53 | 2006 |
| Pharmacology MA Clark, RA Harvey, R Finkel, JA Rey, K Whalen Lippincott Williams & Wilkins, 2011 | 49 | 2011 |
| Lumateperone: a novel antipsychotic for schizophrenia J Greenwood, RB Acharya, V Marcellus, JA Rey Annals of Pharmacotherapy 55 (1), 98-104, 2021 | 41 | 2021 |
| Phentermine/Topiramate extended-release capsules (qsymia) for weight loss DJ Lonneman Jr, JA Rey, BD McKee Pharmacy and Therapeutics 38 (8), 446, 2013 | 40 | 2013 |
| Atypical antipsychotics in children with pervasive developmental disorders B Chavez, M Chavez-Brown, MA Sopko, JA Rey Pediatric Drugs 9, 249-266, 2007 | 40 | 2007 |
| Invega Trinza: the first four-times-a-year, long-acting injectable antipsychotic agent N Daghistani, JA Rey Pharmacy and Therapeutics 41 (4), 222, 2016 | 36 | 2016 |
| Prevalence of hazardous alcohol use among pharmacy students at nine US schools of pharmacy C English, JA Rey, LS Schlesselman Pharmacy Practice 9 (3), 162, 2011 | 30 | 2011 |
| Brexpiprazole (Rexulti): a new monotherapy for schizophrenia and adjunctive therapy for major depressive disorder S Eaves, JA Rey Pharmacy and Therapeutics 41 (7), 418, 2016 | 27 | 2016 |
| Lippincott's illustrated reviews M Clark, R Finkel, J Rey, K Whalen, R Harvey Lipincott Williams and Wilkins: Philadelphia etc, 2012 | 25 | 2012 |
| Flibanserin (Addyi): the first FDA-approved treatment for female sexual interest/arousal disorder in premenopausal women C English, A Muhleisen, JA Rey Pharmacy and Therapeutics 42 (4), 237, 2017 | 24 | 2017 |
| Valbenazine (Ingrezza): The first FDA-approved treatment for tardive dyskinesia S Uhlyar, JA Rey Pharmacy and Therapeutics 43 (6), 328, 2018 | 23 | 2018 |
